What types of cardiac valve replacements are available and what anticoagulation is required for each?

Cardiac Valve Replacement Types and Anticoagulation Requirements

All mechanical valves require lifelong warfarin anticoagulation, while bioprosthetic valves need only 3-6 months of warfarin followed by aspirin alone in most cases.

Valve Types Available

Mechanical Valves

• Bileaflet valves (most common modern design)
• Single-tilting disc valves (e.g., Medtronic Hall)
• Older generation valves (e.g., Starr-Edwards ball-in-cage)
• On-X valve (newer design with potentially lower anticoagulation needs)

Bioprosthetic Valves

• Surgical bioprostheses (porcine or bovine pericardial tissue)
• Transcatheter valves (TAVR/TAVI)

---

Anticoagulation by Valve Type and Position

Mechanical Valves - Lifelong Anticoagulation Required 1, 2

Aortic Position:

• Bileaflet or current-generation single-tilting disc: Warfarin targeting INR 2.5 (range 2.0-3.0) if no risk factors 1, 2
• With risk factors (atrial fibrillation, prior thromboembolism, LV dysfunction, hypercoagulable state): Warfarin targeting INR 3.0 (range 2.5-3.5) 1, 2
• Older generation valves (Starr-Edwards, other disc valves): Warfarin targeting INR 3.0 (range 2.5-3.5) 1

Mitral Position:

• All mechanical valves: Warfarin targeting INR 3.0 (range 2.5-3.5) regardless of valve type 1, 2

Add Aspirin to All Mechanical Valves:

• Aspirin 75-100 mg daily in addition to warfarin for all mechanical valves 1, 2

Special Case - On-X Valve:

• After 3 months post-surgery in aortic position with no risk factors: May use lower INR 1.5-2.0 plus aspirin 75-100 mg daily 1, 2

---

Bioprosthetic Valves - Time-Limited Anticoagulation 1, 2

Initial Period (First 3-6 Months):

• Warfarin targeting INR 2.5 (range 2.0-3.0) for 3-6 months after surgical aortic or mitral valve replacement in patients at low bleeding risk 1, 2
• This addresses the highest thromboembolism risk period before complete endothelialization

Long-Term (After Initial Period):

• Aspirin 75-100 mg daily indefinitely for all bioprosthetic valves without other anticoagulation indications 1, 2

TAVR-Specific:

• Dual antiplatelet therapy (aspirin 75-100 mg + clopidogrel 75 mg) for 3-6 months may be reasonable 2
• Alternative: Warfarin INR 2.5 for at least 3 months 2
• Avoid: Rivaroxaban 10 mg + aspirin is contraindicated (increased mortality/bleeding in trials) 2

---

Critical Caveats and Pitfalls

Direct Oral Anticoagulants (DOACs):

Never use DOACs for mechanical valves - dabigatran is contraindicated and other DOACs are not recommended 2. The RE-ALIGN trial showed increased thrombotic and bleeding complications with dabigatran in mechanical valves.

Risk Factors Requiring Higher INR:

When present, these mandate higher anticoagulation targets:

• Atrial fibrillation
• Prior thromboembolism
• Left ventricular dysfunction (EF <35%)
• Hypercoagulable conditions

INR Monitoring:

Maintain patients at a specific INR target value, not just within range 1. Fluctuations in INR correlate with increased complications. Use dedicated anticoagulation clinics when possible - they reduce bleeding and thrombotic complications compared to standard care 1.

Bioprosthetic Valve Thrombosis:

Recent evidence shows subclinical leaflet thrombosis occurs more frequently than previously recognized 1. This supports the rationale for extending anticoagulation up to 6 months post-implantation, particularly for mitral position bioprostheses where thromboembolism risk is higher.

Bleeding Risk Assessment:

The decision for 3 versus 6 months of anticoagulation in bioprosthetic valves depends on individual bleeding risk. Patients at high bleeding risk should receive the shorter 3-month course 1.